

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Morahan, G;Chandler, D;Lopaticki, S;Huang, D;Hunter, M;Angelicheva, D;Kilpatrick, T;King, RHM;Kalaydjieva, L

Title:

The stretcher spontaneous neurodegenerative mutation models Charcot-Marie-Tooth disease type 4D

Date:

2013-02-13

Citation:

Morahan, G., Chandler, D., Lopaticki, S., Huang, D., Hunter, M., Angelicheva, D., Kilpatrick, T., King, R. H. M. & Kalaydjieva, L. (2013). The stretcher spontaneous neurodegenerative mutation models Charcot-Marie-Tooth disease type 4D. F1000research, 2, pp.46-. <https://doi.org/10.12688/f1000research.c>.

Persistent Link:

<https://hdl.handle.net/11343/262259>

License:

CC BY



RESEARCH ARTICLE

The stretcher spontaneous neurodegenerative mutation models Charcot-Marie-Tooth disease type 4D [v1; ref status: indexed, <http://f1000r.es/8c>]

David Chandler^{1,7}, Sash Lopaticki³, Dexing Huang⁴, Michael Hunter^{1,2}, Dora Angelicheva^{1,2}, Trevor Kilpatrick⁵, Rosalind HM King⁶, Luba Kalaydjieva^{1,2}, Grant Morahan¹⁻³

¹Western Australian Institute for Medical Research and Centre for Diabetes Research, University of Western Australia, Perth, 6000, Australia

²Centre for Medical Research, University of Western Australia, Perth, 6000, Australia

³The Walter and Eliza Hall Institute of Medical Research, Victoria, 3065, Australia

⁴St Vincent's Institute of Medical Research, Victoria, 3010, Australia

⁵Howard Florey Institute, Victoria, 3010, Australia

⁶Department of Clinical Neurosciences, Institute of Neurology University College London, London, NW3 2PF, UK

⁷Australian Genome Research Facility, Perth, 6000, Australia

v1 First published: 13 Feb 2013, 2:46 (doi: [10.12688/f1000research.2-46.v1](https://doi.org/10.12688/f1000research.2-46.v1))
Latest published: 13 Feb 2013, 2:46 (doi: [10.12688/f1000research.2-46.v1](https://doi.org/10.12688/f1000research.2-46.v1))

Abstract

Mice affected by a spontaneous mutation which arose within our colony exhibited a neuromuscular phenotype involving tremor and characteristic stretching of the rear limbs. The mutant, named *stretcher*, was used to breed a backcross cohort for genetic mapping studies. The gene responsible for the mutant phenotype was mapped to a small region on mouse chromosome 15, with a LOD score above 20. Candidate genes within the region included the *Ndr1* gene. Examination of this gene in the mutant mouse strain revealed that exons 10 to 14 had been deleted. Mutations in the human orthologue are known to result in Charcot-Marie-Tooth disease type 4D (CMT4D) a severe early-onset disorder involving Schwann cell dysfunction and extensive demyelination. The *stretcher* mutant mouse is more severely affected than mice in which the *Ndr1* gene had been knocked out by homologous

recombination. Our results demonstrate that the *Ndr1*^{str} mutation provides a new model for CMT4D, and demonstrate that exons 10 to 14 of *Ndr1* encode amino acids crucial to the appropriate function of *Ndr1* in the central nervous system.

Article Status Summary

Referee Responses

Referees	1	2	3
v1 published 13 Feb 2013	 report	 report	 report

1 Rhona Mirsky, University College London
UK

2 Francesc Palau, Centro de Investigación
Príncipe Felipe (CIPF) Spain

3 Angelo Schenone, University of Genoa
Italy

Latest Comments

No Comments Yet

Corresponding author: Grant Morahan (gem@waimr.uwa.edu.au)

How to cite this article: Chandler D, Lopaticki S, Huang D *et al.* (2013) **The stretcher spontaneous neurodegenerative mutation models Charcot-Marie-Tooth disease type 4D [v1; ref status: indexed, <http://f1000r.es/8c>]** *F1000Research* 2013, 2:46 (doi: [10.12688/f1000research.2-46.v1](https://doi.org/10.12688/f1000research.2-46.v1))

Copyright: © 2013 Chandler D *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Grant information: This work was supported by Program Grants 516700 and 37612600 from the National Health and Medical Research Council of Australia to GM; NHMRC grants to LK; by grant DP110102067 from the Australian Research Council; and by L'Association Francaise contre les Myopathies (RHMK and LK). GM is supported by the Diabetes Research Foundation of Western Australia.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: No competing interests were disclosed.

First published: 13 Feb 2013, 2:46 (doi: [10.12688/f1000research.2-46.v1](https://doi.org/10.12688/f1000research.2-46.v1))

First indexed: 07 May 2013, 2:46 (doi: [10.12688/f1000research.2-46.v1](https://doi.org/10.12688/f1000research.2-46.v1))

Introduction

Over 60 spontaneous mouse mutations that exhibit neurological disorders including movement abnormalities or epilepsy conditions are listed in the [Mouse Genome Informatics database](#). Most of these mutations have been defined at the molecular level. Identifying the genes affected has provided insights into the molecular basis of neurological functions; some examples are reviewed in^{1,2}. The availability of animal models of disease aids in understanding its molecular basis and is valuable in the search for new treatments. Nevertheless, many neurological diseases of humans still lack satisfactory animal models.

Previously we had mapped a locus, *Idd11*, which conferred susceptibility to type 1 diabetes in the NOD/LtJ mouse strain³. During the production of congenic mice bearing the C57BL/6J (B6) resistance allele of *Idd11*^{3,4} on the NOD background in our laboratory, a spontaneous mutation arose. These mutant mice exhibited a neurological defect. This paper describes the phenotypic characterization of these mutant mice, as well as mapping, identification and characterization of the mutant gene.

Materials and methods

Mice

Mouse work was performed with ethics approval from the Royal Melbourne Hospital Animal Ethics Committee and from the Animal Ethics Committee of The University of Western Australia. All procedures conformed to the Guidelines for the Care and Use of Experimental Animals described by the National Health and Medical Research Council of Australia. BALB/c, C57BL/6J (B6), DBA/2 and NOD/LtJ (NOD) mice were obtained from either the specific-pathogen free colonies of The Walter and Eliza Hall Institute of Medical Research or from the Animal Resources Centre (Murdoch, Western Australia). NOD.*Slc9a1*^b congenic mice⁴ were maintained in conventional M1 “shoe box” mouse cage (335mm Long x 160mm Wide x 130mm High).

Each cage comprised of 1 male and 1 female with litters being weaned from the box at 3 weeks of age. All animals were provided with food and water *ad libitum*, aspen wood bedding and an environment enrichment consisting of tissue paper for nesting. All

animals were cared for by specialist trained staff with experience in clinical observations of ill health, and behaviour irregularities. A vet was on site to provide an opinion to any observations and instigate necropsy if required. Animals that exhibited ill health were euthanased in pre-charged carbon dioxide chambers. The mice displaying the neurological defect, named *stretcher* (*str*), were intercrossed with BALB/c mice obtained from The Walter and Eliza Hall Institute of Medical Research. A congenic strain, BALB/c.*str* was developed after 10 generations of backcrossing to BALB/c, selecting for retention of NOD-derived alleles at markers on chromosome 15. To map the *str* mutation, we chose to mate NOD.*Slc9a1*^b mutant mice to a third strain, DBA/2 (D2). This was done because the NOD.*Slc9a1*^b mice already had an introduced B6 chromosome region which could potentially complicate mapping.

Genotyping and gene mapping

Conventional microsatellite genotyping was performed using MIT markers⁵ under standard conditions as previously described³. Novel markers were also developed as follows and are listed in [Table 1](#). cDNA sequences of genes previously mapped to the region were BLASTed against GENBANK DNA databases to retrieve genomic sequences. Genomic sequences were also retrieved from the mouse genome sequence⁶ as reported in the NCBI 37 July 2007 assembly ([UCSC Genome Browser](#)). Simple sequence length repeats were selected and primers were designed using the Primer3 program⁷. Primer sequences are listed in [Table 1](#). These were used to amplify the relevant alleles from NOD and DBA/2 DNA. LOD scores and significance thresholds were calculated as described by Lander and Kruglyak (1995)⁸.

RNA isolation, cDNA synthesis and sequencing

Whole kidneys from wild-type BALB/c mice or mutant mice euthanised by exposure to carbon dioxide gas were homogenised in 500µl of Triazol (Gibco) reagent and RNA was extracted according to the manufacturer's instructions. For cDNA synthesis, 2µg of RNA was reverse transcribed using 1 x reverse transcription buffer (Promega), 1U of RNase inhibitor (Invitrogen), 2mM of dNTPs, 50ng/µl of random hexamers (Promega), and 8U of MMLV-reverse transcriptase (Promega) in a total volume of 20µl. Reaction mixes were incubated at 42°C for 60 minutes and the reaction stopped by

Table 1. Primers used to amplify novel markers. Simple sequence length repeats were found from inspection of relevant genomic sequences. The location of the nearest known gene, the genomic position (in Mb from the UCSC July 2007 freeze) of the repeat; the primers used to amplify it; the annealing temperature used (Tm), and the sizes of alleles from B6, DBA/2 and NOD mice, are indicated.

Marker	Gene	Mb	Left primer (5'-3')	Right primer (5'-3')	Tm	B6	DBA/2	NOD
D15Mor1	<i>Kcnq3</i>	66.1	ATGTGTGCTGCTTTGAGCTG	TGCTATGTATCCACACAGCAAA	60	235	235	180
D15Mor2	<i>Tgn</i>	66.5	CTGCCATGGCTTCATTTTCT	GCAAATGCCAGGGTTCTGTA	60	230	220	230
D15Mor3	<i>B8C052212</i>	66.6	CCATACCCCAGAAAGAAAAG	TCCTTTAACATGATGGGAGA	56	128	128	128
D15Mor4	<i>Ndrp1</i>	66.8	AGGTCAGACAGGGTCAGCTAAG	CACATCCTCTCCCACTGAGG	60	155	155	150
D15Mor5	<i>Siat4</i>	66.9	ATGTCTGCTGAGTGCTGAGG	GATGCCACCCTCTACACAT	59	194	194	235
D15Mor6	<i>Etoile</i>	68.5	CCAGGATTTCTTTGGTCTTCTTT	CATGTACCAGGTGCCATGAA	60	193	193	188

heat inactivation at 95°C for 10 minutes. The cDNA was used as a template for the amplification of a PCR product spanning exon 6 to 15 of the *Ndrp1* gene. The reaction consisted of 1x PCR buffer, 2.5mM MgCl₂, 5mM dNTPs, 1.5U Taq polymerase (Kappa), 20ng of each primer (5' GAGGACATGCAGGAGATCAC 3' and 5' CAGAGGCTGTGCGGGACC 3') and water in a total volume of 50µl. PCR cycling conditions consisted of initial denaturation at 95°C followed by 40 cycles of denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds and extension at 72°C for 45 seconds with a final extension step at 72°C for 7 minutes. The products were cleaned with PCR purification columns (Qiagen) and sequenced using BigDye Terminator chemistry (Life Technologies).

Northern blotting

For northern blotting, 5µg of RNA was electrophoresed on a 1.2% agarose/formamide gel for 2 hours in MOPS buffer. The RNA was transferred to a nitrocellulose membrane via capillary-wick blotting in SSC buffer (Sigma-Aldrich) for 3 hours and the membrane was dried in an oven set at 80°C for ten minutes. The RNA was fixed onto the membrane by a 4 minute exposure to UV light (312nm) in a UV cabinet. A DNA probe was constructed from a 233bp PCR product spanning exons 2 to 4 of *Ndrp1* amplified from mouse kidney cDNA using primers 5' GACCTCGCTGAGGTGAAGCC 3' and 5' GTGATCTCCTGCATGTCCTC 3'. The PCR product was labelled with ³²P-CTP using a Random Primed Labelling kit (Roche) according to the manufacturer's instructions. The membrane was incubated in 3ml of Ultrahyb[®] hybridization solution (Ambion) for 30 minutes at 42°C and replaced with 5ml of fresh solution containing the denatured labelled probe (activity of 6.0 x 10⁵ cpm/ml). Hybridization was carried out with rotation at 42°C for 24 hours. The membrane was then washed twice in 2x SSC, 0.1% SDS buffer pre-warmed to 42°C for 10 minutes and twice with 0.1xSSC, 0.1% SDS buffer for 15 minutes. The membrane was wrapped in cling film and exposed to Medical X-Ray film for 16 hours at -80°C. The film was developed on an AGFA CP100 processor.

Western blotting

For isolation of total protein, sciatic nerves were dissected and homogenised in RIPA buffer (1% Nonidet P-40, 0.1% SDS, 0.5% deoxycholate (Sigma-Aldrich), 150mM NaCl, 50mM Tris pH 8.0, 10µg/ml aprotinin, 1mM PMSF, 1mM benzamide (Sigma-Aldrich), 0.1mM Na₃VO₄) and centrifuged at 13,000rpm for 20 minutes at 4°C. The supernatant was transferred to a new tube and quantitated. 10µg of protein was loaded into single wells of a 12% SDS-PAGE stacking gel (Invitrogen) and electrophoresed at 125V for 30 minutes, and 200V for approximately 1 hr. Proteins were transferred to PVDF membranes (Invitrogen) by western blotting at 30V overnight at 4°C. The membranes were probed first with an affinity-purified polyclonal rabbit antibody raised against the full-length NDRG1 protein (A gift from K. Kokame and T. Miyata). After exposure and subsequent stripping, the membrane was then re-probed with a goat polyclonal IgG directed against the N-terminus of the human NDRG1 protein (Santa Cruz Biotech). Immuno-labelled protein bands were visualised using the ECL+ Chemiluminescence kit (Amersham Biosciences) and exposure to Hyperfilm[™] ECL Chemiluminescence film (Amersham Biosciences).

DNA sequencing

Primers were derived from the *Ndrp1* genomic sequence and used to amplify DNA from B6, NOD/LtJ, and BALB/c.*str* mice. Sequencing was performed using the Big Dye terminator kit (Life Technologies) followed by capillary electrophoresis on a 3730 DNA analyser (Life Technologies).

Bioinformatics and model construction

Hypothetical protein models were constructed from the *Ndrp1*^{str} cDNA sequence using The HMMSTR/Rosetta Server (available at <http://www.bioinfo.rpi.edu/bystrc/hmmstr/server.php>) This software implements the HMMSTR (a hidden Markov model for local and secondary structure prediction) and Rosetta (a Monte Carlo Fragment Insertion protein folding program) programs to predict the structure of proteins⁹. Wild-type and mutant protein sequences were analysed at <http://www.predictprotein.org/> to determine whether esterase classification was retained.

Results

Phenotype of the mutant *stretcher* mice

The spontaneous mutation was observed in our NOD.*Slc9a1*^b congenic mouse strain⁴ (referred to as NOD.*lidd11b* in that paper). The mice showed a characteristic stretching of the rear limbs, especially when they were handled for examination (Figure 1). This feature inspired the mutant strain to be named *stretcher* (*str*). The characteristic stretching was accompanied by tremor. Mice also clasped their hind limbs when suspended. The phenotype was most noticeable after 5 weeks of age and progressively worsened, so that after 15 weeks the mice became weak and showed severe tremor of the hind limbs.

Because the strain in which the mutation arose develops type 1 diabetes⁴, there was a danger of losing the mutant stocks, so we



Figure 1. *Stretcher* mutant mouse phenotype. The *stretcher* mutant is characterized by the stretching and "freezing" of the hind limbs, as illustrated in this photograph. The trait is most apparent when the mice are challenged with some behavioural intervention (e.g. handling for clinical examination).

introgressed the *str* mutation onto the nondiabetic strain, BALB/c. In general, though they are fertile, the male *str* mice have difficulty in mating. Therefore, the BALB/c.*str* strain was derived by 10 generations of backcrossing females to BALB/c males (selecting for linked markers that were developed as described below). This strain was maintained by sib mating, taking care to set up brother-sister pairs as soon as they reached breeding age.

Mapping of the *str* gene

At the same time as the congenic mice were being produced, affected NOD.*Slc9a1^b* mice were also mated with DBA/2 mice in order to map the *str* locus. The F1 offspring were unaffected, so F2 progeny were produced and observed for the *stretcher* phenotype. DNA samples from 58 affected F2 mice and 269 unaffected mice were genotyped with markers distributed across the genome. Linkage was observed to markers only on chromosome 15 (Figure 2) with a single-point LOD score = 23.9 at *D15Mit63*. High resolution genotyping was then performed on both affected and unaffected F2 mice. In this way, it was possible to map the *str* locus to an interval of approximately 2cM between the markers *D15Mit233* and *D15Mit144* (Figure 3B). We developed simple sequence length repeat polymorphic markers associated with a number of genes that mapped to the general area, including *Kcnq3*, *Siat4a* and *Etoile* (Table 1). By testing these markers on the panel of F2 mice carrying recombinations between the flanking markers, we excluded *Kcnq3* and *Etoile* as candidates for *str*, since these mapped either centromeric or telomeric

of the critical region, respectively. The *D15Mor1* marker defined the new centromeric boundary of the region in which the *str* locus was mapped. The markers *D15Mor3* and *-4*, defining the *Wisp* and *Siat4a* genes respectively, were located within this interval.

Sequencing the *Ndr1* gene from *str* mice

Although the critical region covers 3Mb, this interval is relatively gene-poor with only 11 known gene transcripts (Figure 3C). However, several of these genes could be considered candidates for the *str* mutation. Of these, *Ndr1* was considered as an especially good candidate since mutations in the human orthologue have been shown to be the cause of a demyelinating peripheral neuropathy, Charcot-Marie-Tooth disease type 4D¹⁰. This disorder is characterized clinically by distal muscle wasting and atrophy, tendon areflexia, and sensory loss, with onset before ten years of age. Therefore, DNA from *str* and wild-type NOD mice was amplified using primers designed to amplify *Ndr1* exons from the genomic sequence.

Sequences of these amplicons were compared to the available genomic sequences but no polymorphisms which would result in amino acid substitutions were identified. During the course of this work, we were unable to amplify exons 10, 11, 12, 13 or 14 from the *str* mice. We reasoned the most likely explanation for this finding was that these exons had been deleted. A number of primers flanking exons 9 and 15 were designed and used in various combinations to test this hypothesis. Eventually, we were able to




Figure 2. Genome scan to map the *str* mutation. Affected F2 progeny (n=49) of (NOD.*str* x DBA/2) F1 parents were typed with microsatellite markers with an average spacing of 20cM over the 19 autosomes. LOD scores were calculated and the dashed line shows the threshold for significance for an F2 genome-wide scan (Lander & Kruglyak, 1995)⁸.




Figure 3. Fine mapping of *str* mutation. **A.** Affected F2 mice were typed with markers on chromosome 15 and LOD scores calculated as in Figure 1. **B.** Affected and unaffected mice which had recombinations within 5 cM of the peak of linkage were genotyped with additional markers. “Mit” denotes *D15Mit* markers, with their given positions in cM; “Mor” denotes novel *D15Mor* markers developed here (see also Table 1). Filled squares = homozygous for allele derived from the NOD.*str* strain; d = at least one copy of DBA/2 allele. **C.** Genomic map of chromosome 15 between the flanking markers *D15Mor1* (which is in an intron of *Kcnq3*) and *D15Mit212*, from 66.1Mb to 68.5 Mb of the UCSC October 2007 Assembly.




Figure 4. Sequence of *NdrG1* allele from *stretcher* mice.

A. Genomic organization of *NdrG1* gene. Exons are represented by filled boxes. The extent of deletion between introns 9 and 14 is indicated; the deleted sequence is indicated by the dotted line and empty boxes. Sequence is shown reversed in comparison to chromosomal orientation. **B.** Sequence flanking the deletion point. Lower case: sequence from intron 9; upper case: intron 14 sequence; underline: sites for primers to amplify deletion allele.

confirm that these exons had in fact been deleted, and to define the exact points between which the deletion had occurred. As shown in **Figure 4**, over 5kb of DNA encompassing exons 10 to 14 had been deleted. The deletion breakpoints are precise, with no addition of nontemplated nucleotides.

Expression of mutant *NdrG1* transcripts and protein

The northern blot analysis revealed a shorter mRNA band, present in the *str* animals at levels similar to the normal product found in WT littermates (**Figure 5A**). The sequence of *NdrG1^{str}* cDNA confirmed that transcripts from the mutant allele were processed with in-frame splicing directly from exons 9 to 15 (**Figure 5C**). A western blot analysis of protein extracted from sciatic nerve revealed a faint band at ~32 kDa, corresponding to the expected molecular mass of the mutant protein missing the 99 amino acids encoded by the deleted exons (**Figure 5B**). Bioinformatic analysis of the abnormal protein showed it could remain classified as a member of the esterases/lipases superfamily. The one letter amino acid codes for both the *ndrg1* WT and mutant proteins are displayed below:

NdrG1 WT

```

msrelhdvdlaevkplvekgesitgllqefdvqeedi-
etlhgslhvtlclgtpkgnrpviltghdigmnhkctcyn-
plfnsedmqeithqfavchvdapggqdgapsfpvgy-
mypsmdqlaemlpvgvlhqfglksvigmgtgagayil-
trfalnnpemveglvlmnnvpcaegwmdwaaskis-
gwtqalpdmvshlfgkeei hnnvevvhtyrqhilndm-
npsnlhlfisaynsrrdleierpmpgthvtlqcpallv-
vgdnspavdavvecnskldptkttllkmadcgglpqisq-
paklaeafkyfvqgmgympsasmtrlmrsrtasgssvt-
  
```

```

slegtrsrstsegsprsrstsegsrsrshtsedarl-
nitpnsgatggnagpksmevsc
  
```

NdrG1 mutant

```

msrelhdvdlaevkplvekgesitgllqefdvqeedi-
etlhgslhvtlclgtpkgnrpviltghdigmnhkctcyn-
plfnsedmqeithqfavchvdapggqdgapsfpvgy-
mypsmdqlaemlpvgvlhqfglksvigmgtgagayilrfa-
lnnpemveglvlmnnvpcaegwmdwaaskisgwtqalp-
dmvshlfgkpklaeafkyfvqgmgympsasmtrlmrsr-
tasgssvtslegtrsrstsegsprsrstsegsrsrsht-
sedarl nitpnsgatggnagpksmevsc
  
```

Further biochemical and structural characterization of the effect of the *stretcher* mutation is described elsewhere¹¹.

Hypothetical model of truncated *NdrG1*

Splice sites for exons 9 and 15 were unaffected by the deletion, and sequencing of the transcripts from the truncated gene showed they could be spliced correctly but would encode a smaller protein product than would the wild-type gene. Hypothetical structures for the normal and mutant proteins were generated using the HMMSTR/Rosetta Server⁹. These models are presented in **Figure 6**. The predicted structure of the truncated protein has an overall similarity to the wild-type, but also contains conformational changes in compensation for the deleted sequences. The major changes to the first third of the molecule may explain the functional deficit of the mutant *NdrG1* molecule in the *str* mice. In view of the low amounts detectable by western blot, the mutant protein is likely to be unstable.

Discussion

Here we report the identification and characterization of the spontaneous mutant *stretcher* mouse, a new model of Charcot-Marie-Tooth 4D disease, with a spontaneous deletion of exons 10–14 of the *NdrG1* gene. We showed that the *NdrG1^{str}* mutation results in low levels of expression of a truncated protein which, compared to the normal protein, is missing 99 amino acids (ie #199 to 297 of the wild-type sequence).

The absent *NdrG1* fragment is due to the deletion in the *NdrG1^{str}* allele. The protein fragment encoded by the deleted exons does not show homology to any particular conserved domain family. The functional importance of the missing domain is highlighted by both the *str* mutation and the human splicing mutation, 2290787G>A which skipped exon 9¹². The reading frame was preserved in both mutations, yet the phenotype in each case was severe peripheral neuropathy. The low detectable levels of aberrant protein suggest that it is unstable, leading to the neurological phenotype observed only in homozygote mutant mice.

The *stretcher* mutation has been characterized by histology¹¹ and is more severely affected in both molecular and behavioural phenotypes than was reported for the *NdrG1*^{-/-} mouse¹³. Though the comparisons should be made on the same genetic background, the milder phenotype of the *NdrG1*^{-/-} mouse is probably due to the knockout strategy




Figure 5. Analysis of *Ndr1*^{str} transcripts and protein product. **A.** A northern blot of RNA from kidneys of wild-type and *str* mice. A 233bp probe spanning exons 2–4 detected in the mutant mouse anRNA species shorter than that seen in the wild-type *Ndr1* RNA (*left panel*). Ethidium bromide-staining of the agarose gel prior to northern transfer showed equal amounts of RNA were loaded (*right panel*). **B.** Western blot of sciatic nerve lysates prepared from wild-type and *str* mutant mice, probed with antibodies raised against the full-length *Ndr1* protein (*left*) or GAPDH (*right*). The full length (43 kDa) *Ndr1* protein was absent from the lysate of the *str* mice but an immunoreactive truncated (32 kDa) protein was present in a lower amount; this size is approximately that predicted for the *Ndr1*^{str} mutant protein. **C.** Chromatograms and translated protein sequences of *Ndr1* cDNA prepared from kidney tissue from 1) wildtype BALB/C and 2) the mutant mouse. The deletion results in the skipping of exons 10–14. Exon 15 is spliced in-frame with exon 9.




Figure 6. Hypothetical structure of wild-type Ndrgr1 (upper) and the Ndrgr1^{str} mutant (lower) proteins. Certain residues are indicated for reference. Cyan, amino acids prior to #199; red, residues encoded by exons deleted in the Ndrgr1^{str} mutant; blue, residues 298-end of wild-type Ndrgr1.

which resulted in excision of the promoter and exon 1, but left intact the initiation codon in exon 2 as well as the rest of the coding region. It seems that these mice are able to produce sufficient amounts of full-length protein to avoid the more extreme phenotype displayed by the *stretcher* mutant mice, and only display the reported milder phenotype of muscle weakness.

We conclude the Ndrgr1^{str} mutant mouse will be a useful resource for investigating the role of *Ndrgr1* in maintaining the myelin sheath, and for modelling the human disorder, Charcot-Marie-Tooth disease 4D.

Author contributions

TK, RHMK, LK and GM designed and analysed experiments. DC, DA, SL, DH and MH performed the research. GM and DC wrote

the manuscript. All the authors reviewed and approved this article.

Competing interests

No competing interests were disclosed.

Grant information

This work was supported by Program Grants 516700 and 37612600 from the National Health and Medical Research Council of Australia to GM; NHMRC grants to LK; by grant DP110102067 from the Australian Research Council; and by L'Association Francaise contre les Myopathies (RHMK and LK). GM is supported by the Diabetes Research Foundation of Western Australia.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Watake K, Zoghbi HY: **Modelling brain diseases in mice: the challenges of design and analysis.** *Nat Rev Genet.* 2003; **4**(4): 296–307.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Baraban SC: **Emerging epilepsy models: insights from mice, flies, worms and fish.** *Curr Opin Neurol.* 2007; **20**(2): 164–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Morahan G, McClive P, Huang D, *et al.*: **Genetic and physiological association of diabetes susceptibility with raised Na⁺/H⁺ exchange activity.** *Proc Natl Acad Sci U S A.* 1994; **91**(13): 5898–902.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Brodnicki TC, McClive P, Couper S, *et al.*: **Localization of Idd11 using NOD congenic mouse strains: elimination of Slc9a1 as a candidate gene.** *Immunogenetics.* 2000; **51**(1): 37–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Dietrich W, Katz H, Lincoln SE, *et al.*: **A genetic map of the mouse suitable for typing intraspecific crosses.** *Genetics.* 1992; **131**(2): 423–47.
[PubMed Abstract](#) | [Free Full Text](#)
6. Waterston RH, Lindblad-Toh K, Birney E, *et al.*: **Initial sequencing and comparative analysis of the mouse genome.** *Nature.* 2002; **420**(6915): 520–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Rozen S, Skaletsky H: **Primer3 on the WWW for general users and for biologist programmers.** *Methods Mol Biol.* 2000; **132**: 365–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Lander E, Kruglyak L: **Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results.** *Nat Genet.* 1995; **11**(3): 241–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Bystroff C, Shao Y: **Fully automated ab initio protein structure prediction using I-SITES, HMMSTR and ROSETTA.** *Bioinformatics.* 2002; **18**(Suppl 1): S54–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Kalaydjieva L, Gresham D, Gooding R, *et al.*: **N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom.** *Am J Hum Genet.* 2000; **67**(1): 47–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. King RH, Chandler D, Lopaticki S, *et al.*: **Ndr1 in development and maintenance of the myelin sheath.** *Neurobiol Dis.* 2011; **42**(3): 368–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Hunter M, Bernard R, Freitas E, *et al.*: **Mutation screening of the N-myc downstream-regulated gene 1 (NDRG1) in patients with Charcot-Marie-Tooth Disease.** *Hum Mutat.* 2003; **22**(2): 129–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Okuda T, Higashi Y, Kokame K, *et al.*: **Ndr1-deficient mice exhibit a progressive demyelinating disorder of peripheral nerves.** *Mol Cell Biol.* 2004; **24**(9): 3949–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Current Referee Status:

Referee Responses for Version 1



Angelo Schenone

Department of Neurology, University of Genoa, Liguria, Italy

Approved: 20 May 2013

Referee Report: 20 May 2013

The title and abstract are appropriate for the content of the article and the abstract does represent a good summary of the work. Design, methods and analysis are nicely explained and indeed appropriate for the topic of the study. Results are definitely important to the research in the field of hereditary neuropathies, as they give insights on the role of the NDRG1 gene in the development of a rare type of CMT (CMT4D). Having good animal models for the different types of CMT and a detailed description of their phenotype (given in the paper published in Neurobiology of Disease- [PMID21303696](#)) is pivotal to unravel disease pathomechanisms and program future therapies. The discussion and conclusions are justified. However, it would have been very helpful to the readers reporting the presence of a canine model of CMT4D which carries a small deletion within the NDRG1 gene. Canine CMT is relatively frequent and, to the best of my knowledge, this is the only model in which a genetic change has been reported.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.



Fransesc Palau

Rare and Genetic Diseases Program , Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain

Approved: 07 May 2013

Referee Report: 07 May 2013

This paper provides new knowledge on the role of the *Ndr1* gene in the biology of peripheral nerve, and more specifically in the pathophysiology of Charcot-Marie-Tooth disease type 4D (CMT4D) caused by mutations in *Ndr1*. Most importantly, the stretcher mouse (*Ndr1*^{str}) provides a very useful tool to investigate in depth the myelin biology and defects associated to NDRG1 protein.

From the experimental aspects, the authors show a nice and classical genetic approach to isolate and characterize the gene in a spontaneous mutant mouse, which include phenotyping, gene mapping, gene expression and molecular genetics to define the mutation. Further histological phenotypes have been reported elsewhere, as indicated by the authors ([Ref. 11- King et al.](#)). It is noteworthy, the finding of a more severe phenotype in the stretcher mouse than in the *Ndr1*^{-/-}, which suggests the protein domain encoded by exons 10-14 are very important in protein function (a biological aspect that deserves more

attention in future investigations). In this way, the paper remains a description of an animal model of CMT4D, and I want to state the relevance to move forward to the functional role of NDRG1 in the physiology of the Schwann cell and Schwann cell-axon interaction.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.



Rhona Mirsky

Department of Cell and Developmental Biology, University College London, London, UK

Approved: 17 April 2013

Referee Report: 17 April 2013

The title and abstract are appropriate for the content of the article. The article is clearly written, and the design, methods and analysis are appropriate. The article shows that the mutation is due to deletion of exons 10-14 of the *Ndr1* gene, resulting in an unstable smaller protein, obtained by translation of exons 1-9 and exons 15 and 16 in frame. The functional deficits in the hind limbs appear clearly at about 5 weeks of age – this represents a relatively early onset which can be compared to the early onset seen in human recessive Charcot-Marie-Tooth type 4D which shows an early onset. The model appears to model the human disease phenotype more faithfully than the previously reported *Ndr1* knockout mouse and therefore represents an additional tool for research.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.
